Cas:27979-57-3 5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one manufacturer & supplier

Chemical Name:5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one

CAS.NO:27979-57-3

Synonyms:5,7-dihydroxy-4-methyl-3H-isobenzofuran-1-one;5,7-dihydroxy-4-methylphthalide;4-Methyl-5,7-dihydroxyisobenzofuran-1(3H)-one;5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one;1(3H)-Isobenzofuranone,5,7-dihydroxy-4-methyl;1(3H)-Isobenzofuranone, 5,7-dihydroxy-4-methyl-

Molecular Formula:C₉H₈O₄

Molecular Weight:180.157

HS Code:2932209090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:486.0±44.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.663

PSA:66.76000

Exact Mass:180.042252

LogP:1.17

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5,7-dihydroxy-4-methyl-3H-isobenzofuran-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1(3H)-Isobenzofuranone, 5,7-dihydroxy-4-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1(3H)-Isobenzofuranone,5,7-dihydroxy-4-methyl Use and application,4-Methyl-5,7-dihydroxyisobenzofuran-1(3H)-one technical grade,usp/ep/jp grade.

Related News: Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong autonomous learning to automatically control glycemia. 5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one manufacturer “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. 5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one supplier In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one vendor “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. 5,7-Dihydroxy-4-methyl-2-benzofuran-1(3H)-one factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.